309 related articles for article (PubMed ID: 15104303)
1. Angiomatous meningioma: a clinicopathologic study of 38 cases.
Hasselblatt M; Nolte KW; Paulus W
Am J Surg Pathol; 2004 Mar; 28(3):390-3. PubMed ID: 15104303
[TBL] [Abstract][Full Text] [Related]
2. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature.
Wolfsberger S; Doostkam S; Boecher-Schwarz HG; Roessler K; van Trotsenburg M; Hainfellner JA; Knosp E
Neurosurg Rev; 2004 Oct; 27(4):238-45. PubMed ID: 15168138
[TBL] [Abstract][Full Text] [Related]
3. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
Nassehi D
Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
[TBL] [Abstract][Full Text] [Related]
4. Ki-67 index as a predictive marker of meningioma recurrence following surgical resection.
Mizrachi M; Hartley B; Saleem S; Hintz E; Ziemba Y; Li J; Goenka A; Schulder M
J Clin Neurosci; 2024 Jun; 124():15-19. PubMed ID: 38631196
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
6. Angiomatous Meningiomas Have a Very Benign Outcome Despite Frequent Peritumoral Edema at Onset.
Hua L; Luan S; Li H; Zhu H; Tang H; Liu H; Chen X; Bozinov O; Xie Q; Gong Y
World Neurosurg; 2017 Dec; 108():465-473. PubMed ID: 28844928
[TBL] [Abstract][Full Text] [Related]
7. Secretory meningioma: clinical, histologic, and immunohistochemical findings in 31 cases.
Probst-Cousin S; Villagran-Lillo R; Lahl R; Bergmann M; Schmid KW; Gullotta F
Cancer; 1997 May; 79(10):2003-15. PubMed ID: 9149029
[TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic iron deposition is associated with the expression of oxidative DNA damage marker in meningiomas.
Nagaishi M; Yokoo H; Osawa T; Nobusawa S; Tanaka Y; Ikota H; Yoshimoto Y; Nakazato Y
Neuropathology; 2013 Oct; 33(5):526-32. PubMed ID: 23406462
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
[TBL] [Abstract][Full Text] [Related]
10. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
[TBL] [Abstract][Full Text] [Related]
11. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.
Abramovich CM; Prayson RA
Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826
[TBL] [Abstract][Full Text] [Related]
13. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
14. Correlation of apparent diffusion coefficient with Ki-67 proliferation index in grading meningioma.
Tang Y; Dundamadappa SK; Thangasamy S; Flood T; Moser R; Smith T; Cauley K; Takhtani D
AJR Am J Roentgenol; 2014 Jun; 202(6):1303-8. PubMed ID: 24848829
[TBL] [Abstract][Full Text] [Related]
15. MIB-1 staining index of pediatric meningiomas.
Sandberg DI; Edgar MA; Resch L; Rutka JT; Becker LE; Souweidane MM
Neurosurgery; 2001 Mar; 48(3):590-5; discussion 595-7. PubMed ID: 11270550
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
Karamitopoulou E; Perentes E; Tolnay M; Probst A
Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy.
Shino A; Nakasu S; Matsuda M; Handa J; Morikawa S; Inubushi T
J Neurosurg; 1999 Dec; 91(6):928-34. PubMed ID: 10584837
[TBL] [Abstract][Full Text] [Related]
18. PCNA, Ki-67 and hTERT in residual benign meningiomas.
Maes L; Kalala JP; Cornelissen M; De Ridder L
In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
[TBL] [Abstract][Full Text] [Related]
19. Absence of histological signs of tumor progression in recurrences of completely resected meningiomas.
Schiffer D; Ghimenti C; Fiano V
J Neurooncol; 2005 Jun; 73(2):125-30. PubMed ID: 15981101
[TBL] [Abstract][Full Text] [Related]
20. "Rhabdoid" meningioma: an aggressive variant.
Perry A; Scheithauer BW; Stafford SL; Abell-Aleff PC; Meyer FB
Am J Surg Pathol; 1998 Dec; 22(12):1482-90. PubMed ID: 9850174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
